BOCA RATON, Fla., Feb. 14, 2019 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloid scars with Image-Guided Superficial Radio Therapy (IGSRT), announced today the publication of consensus guidelines on the use of Superficial Radio Therapy (SRT) for treating both NMSC and recurrent keloid scars in February 2019 issue of The Journal of Clinical and Aesthetic Dermatology.
Consensus was reached for guidelines on various aspects of SRT use, including appropriate tumor types; suitable anatomical areas; energy, fractions, and scheduling recommendations for SRT; safety factors; as well as treatment recommendations for keloid scars, based the literature and on both the opinions of the expert group and a survey of experienced users. The expert group that developed the guidelines has a combined 250 years of dermatology practice and 78 years of experience with SRT specifically, having treated more than 9,000 patients with SRT.
“With decades of clinical use and research, 1000+ doctors around the world use SRT as a highly effective, non-invasive treatment option for NMSC and keloid scars for their patients. It is vital that the medical community has clear, concise, published treatment guidelines based on a thorough review of all literature and expert opinion on SRT to date,” said Mark S. Nestor, M.D., PH.D., Director, Center for Clinical and Cosmetic Research, Aventura FL and Voluntary Professor, the Department of Dermatology and Cutaneous Surgery and Department of Surgery, Division of Plastic Surgery at University of Miami Miller School of Medicine, and the lead author of the guidelines. “Our goal in forming these guidelines is to fill an important knowledge gap regarding the use of SRT and demonstrate its overarching efficacy with various patient populations across the globe.”
The following is a link to the consensus guidelines:
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT into its portfolio of treatment devices, the SRT-100TM, SRT-100+TM and SRT-100 VisionTM. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. Sensus also offers Sensus Laser Systems, three next-generation devices that showcase the latest in technology and function for the aesthetic dermatology market.
For more information, visit http://17s.9e1.myftpupload.com.
This press release includes statements that are, or may be deemed, ‘forward-looking statements.’ In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential” or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words.
By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release, as a result of, among other factors: our ability to achieve and sustain profitability; market acceptance of our product lines; our ability to successfully commercialize our products; our ability to compete effectively in selling our products and services, including responding to technological change and cost containment efforts of our customers; our need and ability to obtain additional financing in the future, as well as complying with the restrictions our existing revolving credit facility imposes; our ability to expand, manage and maintain our direct sales and marketing organizations; our actual financial results may vary significantly from forecasts and from period to period; our ability to successfully develop new products, improve or enhance existing products or acquire complementary products, technologies, services or businesses; our ability to obtain and maintain intellectual property of sufficient scope to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; market risks regarding consolidation in the healthcare industry; the willingness of healthcare providers to purchase our products if coverage, reimbursement and pricing from third party payors for procedures using our products declines; the level and availability of government and third party payor reimbursement for clinical procedures using our products; our ability to effectively manage our anticipated growth, including hiring and retaining qualified personnel; the regulatory requirements applicable to us and our competitors; our ability to manufacture our products to meet demand; our reliance on third party manufacturers and sole- or single-source suppliers; our ability to reduce the per unit manufacturing costs; our ability to efficiently manage our manufacturing processes; the regulatory and legal risks, and certain operating risks, that our international operations subject us to; off label use of our products; the fact that product quality issues or product defects may harm our business; the accuracy of our financial statements and accounting estimates, including allowances for accounts receivable and inventory obsolescence; any product liability claims; limited trading in our shares and the concentration of ownership of our shares; cyberattacks and other data breaches and the adverse effect on our reputation; new legislation, administrative rules, or executive orders, including those that impact taxes and international trade regulation; the provisions in our certificate of incorporation, bylaws, or Delaware law that discourage takeovers or that limit certain disputes to be brought exclusively in the Delaware Court of Chancery; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; and other risks described from time to time in Sensus Healthcare’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K.
In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release. You should read carefully our “Cautionary Note Regarding Forward-Looking Information” and the factors described in the “Risk Factors” section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.
Kim Sutton Golodetz
LHA Investor Relations
View original content to download multimedia:http://www.prnewswire.com/news-releases/leading-dermatologists-develop-consensus-guidelines-for-the-use-of-superficial-radiation-therapy-to-treat-non-melanoma-skin-cancers-and-keloids-300795634.html
SOURCE Sensus Healthcare